Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
  • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
  • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents

Definitions

• the present invention relates to a composition for improving fatigue, sleep disorders, eye fatigue, and menopausal symptoms.
• Menopausal symptoms are symptoms that appear during menopause due to the decline in ovarian and hormonal function caused by aging, and include, for example, vasomotor symptoms such as hot flashes, pain such as headaches and muscle pain, decline in mental and sleep quality, and general fatigue. Although more prevalent in women, they are also seen in men. Furthermore, regardless of whether they are in menopause or not, many modern people suffer from fatigue, sleep disorders, eye fatigue, and other conditions caused by psychological or physical stress. It is known that germinated fermented bean extracts improve these symptoms (Patent Document 1).
• Lactobacillus plantarum L-137 strain can treat, prevent or improve fatigue, sleep disorders, eye fatigue and menopausal symptoms.
• the inventors have examined a large number of materials in search of one that has the effect of treating, preventing or improving fatigue, sleep disorders or eye fatigue, and menopausal symptoms. As a result, they have surprisingly discovered that the lactic acid bacteria Lactobacillus plantarum L-137 strain (hereinafter sometimes referred to as "L-137 strain”) has such desirable effects. This was a surprising discovery made by the inventors. After further investigations, the inventors have completed the present invention.
• the present invention is as follows.
• [1] A composition for treating, preventing, or ameliorating one or more symptoms selected from the group consisting of fatigue, sleep disorders, and eye fatigue, characterized by containing Lactobacillus plantarum L-137 or a processed product thereof.
• [2] A composition for treating, preventing, or ameliorating menopausal symptoms, comprising Lactobacillus plantarum L-137 or a processed product thereof.
• composition according to [2] which is used for treating, preventing, or improving one or more symptoms selected from the group consisting of the following (i) to (xii): (i) vasomotor-like symptoms; (ii) paresthesia-like symptoms; (iii) insomnia; (iv) nervousness; (v) depression; (vi) dizziness; (vii) general malaise; (viii) joint and/or muscle pain; (ix) headache; (x) palpitations; (xi) feeling of being on the move; and (xii) eye fatigue.
• the composition described in [4], wherein the food or beverage is a food additive or a supplement.
• [6] Use of Lactobacillus plantarum L-137 or a processed product thereof for the manufacture of a medicine for treating, preventing, or ameliorating at least one symptom selected from the group consisting of fatigue, sleep disorders, and eye fatigue.
• [7] Use of Lactobacillus plantarum L-137 or a processed product thereof for the manufacture of a medicine for treating, preventing, or ameliorating menopausal symptoms.
• a method for treating, preventing, or ameliorating menopausal symptoms by administering Lactobacillus plantarum L-137 or a processed product thereof to a subject.
• compositions for treating, preventing or improving fatigue, sleep disorders or eye fatigue, and menopausal symptoms are useful for treating, preventing or improving various menopausal symptoms, such as vasomotor disorder-like symptoms, sensory disorder-like symptoms, insomnia, nervousness, depression, dizziness, general malaise, joint pain and/or muscle pain, headache, palpitations, tingling sensation and eye fatigue.
• various menopausal symptoms such as vasomotor disorder-like symptoms, sensory disorder-like symptoms, insomnia, nervousness, depression, dizziness, general malaise, joint pain and/or muscle pain, headache, palpitations, tingling sensation and eye fatigue.
• it is possible to provide a method for producing these compositions are possible to provide a method for producing these compositions.
• the present invention is used for treating, preventing or improving fatigue, sleep disorder and/or eye fatigue.
• Fatigue is generally a state of decreased activity and efficiency caused by overload on the mind and body due to physical or mental causes, and fatigue is a sense of awareness of the presence of such fatigue.
• Examples of physical fatigue include, but are not limited to, physical fatigue caused by strenuous exercise, muscle training, work, etc.
• examples of mental fatigue include, but are not limited to, stress caused by interpersonal relationships, work worries, changes in environment due to moving or transfer, changes in lifestyle due to marriage or childbirth, and shocking events.
• sleep disorders include, but are not limited to, insomnia, sleep onset disorder, deep sleep disorder, mid-sleep awakening, early awakening, nightmare, sleepwalking, somnolence, parasomnia, hypersomnia, sleep attacks, respiratory-related sleep disorder, apnea, and circadian rhythm sleep disorder.
• insomnia, sleep onset disorder, and deep sleep disorder are treated, prevented, or improved, and more preferably, insomnia is treated, prevented, or improved, but is not limited to, therein.
• Eye fatigue includes, but is not limited to, eye strain, objective or subjective eye fatigue, dry eyes, and itchy eyes. Eye fatigue is preferably induced by light (so-called blue light) stimulation from office automation devices such as smartphones and personal computers, but is not limited to these.
• eye fatigue that is preferably treated, prevented, or improved includes, but is not limited to, objective or subjective eye fatigue and eye strain.
• the target of the composition of the present invention is not limited to menopausal and pre- and post-menopausal individuals or groups described below, but can be individuals or groups of any age.
• menopause is a period of about 5 years before and after menopause (e.g., amenorrhea for 12 months or more) when ovarian function is usually reduced in women, but symptoms may also be observed in women who have had their ovaries removed.
• menopause refers to a period in which the secretion amount of estrogen, a female hormone, is rapidly decreased, but it is not limited to these periods because it varies depending on individuals and groups (e.g., race, era, etc.).
• men do not have menopause and usually do not tend to rapidly decrease male hormones, but the secretion amount of testosterone, a male hormone, may decrease due to environmental changes or stress in addition to aging. It refers to a period in which mental and physical disorders similar to those of women's menopause occur, but it is not limited to these periods because it varies depending on individuals and groups.
• the menopausal symptoms to be treated, prevented, or ameliorated are, for example, one or more selected from the group consisting of the following (i) to (xii), but are not limited thereto.
• vasomotor disorder-like symptoms e.g., but not limited to, hot flashes (e.g., hot flashes, flushing, sweating, etc.), poor circulation, tachycardia, bradycardia, etc.
• sensory disorder-like symptoms e.g., numbness, hyperesthesia, sensory paralysis, etc., including, but not limited to, numbness and dullness in the arms, hands, or lower limbs (e.g., the base of the legs, thighs, knees, calves, shins, ankles, feet, etc.),
• insomnia e.g., the base of the legs, thighs, knees, calves, shins, ankles, feet, etc.
• insomnia e.g., the base of the legs, thighs, knees, calves, shins, ankles, feet, etc.
• insomnia e.g., the base of the legs, thighs, knees, calves, shins, ankles, feet,
• symptoms that are more preferably treated, prevented or ameliorated in the present invention include, but are not limited to, insomnia and/or general fatigue.
• the present invention is preferably used for the treatment, prevention or amelioration of menopausal symptoms in women and men, and more preferably for the treatment, prevention or amelioration of menopausal symptoms in women.
• the composition of the present invention is characterized by containing the lactic acid bacterium Lactobacillus plantarum L-137 strain (Accession No.: FERM BP-08607) or a processed product thereof.
• the lactic acid bacteria Lactobacillus plantarum L-137 used in the present invention has been deposited at the National Institute of Advanced Industrial Science and Technology (currently National Institute of Technology and Evaluation Patent Organism Depositary Center; address: Room 120, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan, 292-0818) under deposit number FERM BP-08607 (transferred from FERM P-15317 deposited on November 30, 1995).
• Lactobacillus plantarum L-137 Even if it is a mutant strain of Lactobacillus plantarum L-137, if it has the characteristics of Lactobacillus plantarum L-137, it is in the category of Lactobacillus plantarum L-137. In addition to Lactobacillus plantarum L-137, other lactic acid bacteria may be contained in the composition of the present invention.
• the Lactobacillus plantarum L-137 or a processed product thereof is preferably contained in an amount of about 0.0001 to 10% by weight, more preferably about 0.001 to 8% by weight, and even more preferably about 0.002 to 4% by weight, based on the total amount of the composition, but is not limited to these ranges.
• the intake amount of the Lactobacillus plantarum L-137 strain of the present invention or a processed product thereof, when administered orally or by injection can be determined depending on the age and weight of the person taking it, symptoms, administration time, dosage form, administration method, combination of drugs, etc.
• Lactobacillus plantarum L-137 it is preferable to set the amount of Lactobacillus plantarum L-137 to be ingested per day by an adult (about 60 kg) in terms of viable bacteria, preferably about 5 ⁇ 10 8 to 2 ⁇ 10 11 cfu (colony forming unit), more preferably about 1 ⁇ 10 9 to 1 ⁇ 10 11 cfu, but this range is not limited.
• the number of times of ingestion can be once or several times a day.
• the above-mentioned dosage may be administered or applied once to several times a day.
• Lactobacillus plantarum L-137 and other lactic acid bacteria may be cultured in any medium such as a natural medium, a synthetic medium, a semi-synthetic medium, etc.
• the lactic acid bacteria may be cultured according to a known method, a method known per se, or a method similar thereto.
• the medium is not particularly limited, and preferably contains, for example, a nitrogen source and/or a carbon source.
• the nitrogen source is not particularly limited, and examples thereof include meat extract, peptone, gluten, casein, yeast extract, and amino acids.
• the carbon source is not particularly limited, and examples thereof include glucose, xylose, fructose, inositol, maltose, starch syrup, koji soup, starch, bagasse, bran, molasses, and glycerin. These may be used alone or in combination of two or more.
• the medium may further contain an inorganic substance.
• the inorganic substance is not particularly limited, and examples thereof include ammonium sulfate, potassium phosphate, magnesium chloride, salt, iron, manganese, molybdenum, and various vitamins, and these may be used alone or in combination of two or more.
• the culture temperature and culture time of Lactobacillus plantarum L-137 and other lactic acid bacteria are not particularly limited as long as the culture can be carried out efficiently.
• the culture temperature may be, for example, usually about 25 to 40 degrees (°C), preferably about 27 to 35°C, and the culture time may be, for example, about 12 to 48 hours.
• the lactic acid bacteria may be cultured by aeration and shaking.
• the pH of the medium is not particularly limited, but in one embodiment of the present invention, the pH may be usually about pH 3 to 6, preferably about pH 4 to 6.
• the "processed product" of the lactic acid bacteria Lactobacillus plantarum L-137 strain is preferably a processed product of the L-137 strain, and examples thereof include, but are not limited to, its culture solution or culture supernatant, residues obtained by filtering or centrifuging the same, ultrasonically disrupted solutions of bacteria, etc.
• the processed product of the present invention also includes, but is not limited to, solutions in which cell walls have been removed by enzymatic or physical treatment, protein or peptide complexes obtained by chemical or salting-out treatment, and concentrates, dried products, or dilutions thereof.
• the L-137 strain may be in the form of live cells, dried cells, centrifuged cells, disrupted cells, or killed cells, but killed cells are preferred from the standpoints of stability, ease of handling, and the like.
• the above-mentioned processed products may be used as they are, or may be freeze-dried, low-temperature dried, spray-dried, L-dried, or a combination of these to form a powder.
• These processed products may also be diluted with an appropriate solvent (water, alcohol, organic solvent, etc.) or may be made into a gel or solid by adding appropriate additives.
• a method for preparing killed cells of Lactobacillus plantarum L-137 and other lactic acid bacteria will be specifically described below.
• the method for preparing the killed cells is not particularly limited as long as the effects of the present invention are not lost, and may be, for example, any of the following methods: (I) a method in which live cells of lactic acid bacteria are separated from the culture solution after the completion of culture, and then the live cells are sterilized or sterilized to kill the cells, (II) a method in which live cells of lactic acid bacteria are sterilized in the culture solution to kill the cells, and then the killed cells are separated from the culture solution, etc.
• Sterilization can be carried out, for example, by filter filtration, but it may also be carried out by other known methods, such as gas sterilization with ethylene oxide or hydrogen peroxide, heat sterilization with gamma rays, electron beam irradiation, high frequency, etc.
• the method for separating the bacterial cells from the culture liquid may be any of various methods commonly used in this field, and is not particularly limited.
• a method may be adopted in which the culture liquid and the bacterial cells are separated by removing the supernatant from the culture liquid by means of centrifugation or the like.
• distilled water is added to the culture liquid, centrifuged, the supernatant is removed, and then, if desired, distilled water is added to the residue from which the supernatant has been removed and the centrifugation is repeated several times.
• a filtration step may be included as a separation operation.
• the above-mentioned bacterial cells are dried using a spray drying device to obtain dried bacteria.
• a spray drying device equipped with an atomizing device capable of forming spray droplets of about 1 to 10 ⁇ m can be preferably used, but is not limited to this.
• the sterilization method is not particularly limited, and examples thereof include heating, ultraviolet irradiation, and formalin treatment.
• the sterilization may be performed on the harvested live bacterial cells, or on a culture solution containing the live bacterial cells.
• the heating temperature is not particularly limited, but may be, for example, usually about 60 to 100 degrees (°C), preferably about 70 to 90 degrees.
• the heating means may be a known method, but is not particularly limited, and may be, for example, a heater or other means.
• the heating time is not particularly limited as long as the sterilization treatment can be sufficiently completed, but, for example, the heating time after the desired temperature is reached may be usually about 5 to 40 minutes, preferably about 10 to 30 minutes.
• the killed bacteria obtained as described above may be further subjected to grinding, crushing, spray drying, low-temperature drying, or freeze drying, or may be mixed with other raw materials (e.g., vitamins, amino acids, oligopeptides, etc.) to obtain a processed product of killed bacteria.
• the processed product of killed bacteria can also be suitably used as killed bacteria.
• compositions of the present invention are for use in food and beverages and/or pharmaceuticals (including veterinary medicines).
• the composition of the present invention is used as an additive for food and beverages.
• a composition for use in food and beverages, as an additive for food and beverages, or as a pharmaceutical can be formulated by appropriately mixing the above-mentioned culture supernatant of the present invention or a processed product thereof, or the L-137 strain or a processed product thereof, with pharma- ceutically acceptable carriers, additives, etc.
• formulation methods and formulation techniques have been well established, so these may be followed.
• the composition may be specifically made into oral preparations such as tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, and emulsions, or parenteral preparations such as injections, infusions, suppositories, ointments, and patches.
• oral preparations such as tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, and emulsions
• parenteral preparations such as injections, infusions, suppositories, ointments, and patches.
• the mixing ratio of the carrier or additive may be appropriately set based on the range normally adopted in the fields of food and beverages, pharmaceuticals, or veterinary medicine.
• carriers include various carriers such as aqueous or oily bases.
• aqueous carriers include water, physiological saline, ethanol, glycerin, polyethylene glycol, propylene glycol, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyacrylic acid, polysaccharide gum-based natural polymers, and the like.
• oily carriers include, but are not limited to, appropriate oils and waxes such as petrolatum, squalane, and paraffin.
• additives include, but are not limited to, enzymes, pH adjusters, preservatives, bactericides, antioxidants, antifungal agents, shelf life improvers, bleaching agents, glossing agents, flavors, sweeteners, acidulants, seasonings, bittering agents, emulsifiers, thickeners, stabilizers, gelling agents, thickening agents, excipients, binders, disintegrants, lubricants, colorants, flavoring agents, etc. Technologies related to these have been well established in the past, so they may be used in the present invention.
• the composition of the present invention when the composition of the present invention is for food and drink, the food and drink includes health foods, functional foods, foods for specified health uses, and foods for patients.
• the form of the food and drink is not particularly limited, but specific examples include tablets, granules, powders, drinks, etc. as so-called nutritional supplements or supplements.
• beverages such as tea drinks, soft drinks, carbonated drinks, nutritional drinks, fruit drinks, and lactic acid drinks
• noodles such as soba, udon, Chinese noodles, and instant noodles
• sweets and breads such as candy, gum, chocolate, snacks, biscuits, jellies, jams, creams, baked goods, and breads
• processed seafood and livestock foods such as ham, sausages, hanpen, and chikuwa
• dairy products such as processed milk and fermented milk
• oils and fats and oil-processed foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressing
• seasonings such as sauces and sauces
• retort pouch foods such as curry, stew, rice bowls, porridge, and zosui
• cold desserts such as ice cream, sherbet, and shaved ice.
• composition of the present invention may contain any component known in the fields of medicine, pharmacology, veterinary medicine, livestock, food, etc., as long as the effect of the present invention is not lost.
• An example of a method for confirming the effect of the composition of the present invention is a method for confirming that a composition containing Lactobacillus plantarum L-137 or a processed product thereof is superior in improving fatigue, sleep disorders, eye fatigue, and menopausal symptoms compared to a composition not containing the L-137 strain or a processed product thereof.
• methods for confirming the effect of improving fatigue, sleep disorders or eye fatigue, and menopausal symptoms include, but are not limited to, for example, a visual analogue scale (VAS) for measuring subjective fatigue, blood oxidative stress markers, a method for measuring the time it takes to fall asleep (sleep onset latency) and the total sleep maintenance time (total sleep time), a forced swim test (FST) using rats or mice, and a method for evaluating the effect based on a questionnaire and Kupperman index described below.
• VAS visual analogue scale
• FST forced swim test
• composition of the present invention is not limited to the treatment, prevention or improvement of menopausal symptoms, but for example, ovariectomized animals (preferably rats, mice, etc.) known as menopausal models may be used to evaluate menopausal symptoms.
• ovariectomized animals preferably rats, mice, etc.
• menopausal models may be used to evaluate menopausal symptoms.
• a method of measuring cell viability when retinal pigment epithelial cells of humans or animals (for example, rabbits, etc.) are irradiated with blue light can be used.
• the composition of the present invention when a subject ingests (administers) the composition of the present invention, can be determined to have the desired effect if the measured values of VAS or blood oxidative stress markers are significantly or significantly lower, or if the sleep onset latency and/or total sleep time are significantly or significantly longer, compared to a control group that does not ingest (or administer) the composition of the present invention.
• the evaluation may be performed according to methods well established in the art, such as methods known in the art other than those described above. Examples of these methods can be seen in the Examples below.
• composition of the present invention When the composition of the present invention is prepared in the form of a food or beverage, a medicine (including veterinary medicine), or a quasi-drug, the food or beverage, the medicine, or the quasi-drug, or its accompanying instructions or packaging box, etc., may state that the composition of the present invention has an effect of improving fatigue, sleep disorders, eye fatigue, and menopausal symptoms.
• a medicine including veterinary medicine
• quasi-drug the food or beverage, the medicine, or the quasi-drug, or its accompanying instructions or packaging box, etc.
• the present invention preferably includes a method for producing a composition for treating, preventing, or ameliorating fatigue, sleep disorders, eye fatigue, and menopausal symptoms, characterized by including a step of mixing Lactobacillus plantarum L-137 or a processed product thereof with a carrier and/or an excipient.
• Preferred carriers for use in the above steps have been well established in the food or pharmaceutical fields, and the present invention may follow suit.
• suitable carriers include aqueous or oily bases.
• aqueous carriers include water, saline, ethanol, glycerin, polyethylene glycol, propylene glycol, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyacrylic acid, polysaccharide gum-based natural polymers, and the like.
• oily carriers include, but are not limited to, suitable oils and waxes such as petrolatum, squalane, and paraffin.
• lactose sucrose, mannitol, corn starch, powdered cellulose, calcium hydrogen phosphate, calcium carbonate, etc. can be preferably used, but are not limited to these.
• the composition of the present invention can be appropriately processed and manufactured by a general method for manufacturing a composition, except for adding Lactobacillus plantarum L-137 or a processed product thereof to the composition.
• the present invention encompasses a method for manufacturing a composition that includes a step of mixing Lactobacillus plantarum L-137 or a processed product thereof with other ingredients, as desired.
• the present invention includes various combinations of the above configurations within the technical scope of the present invention, as long as the effects of the present invention are achieved. In addition, appropriate modifications are possible as long as they fall within the technical scope of the present invention.
• compositions containing Lactobacillus casei L-137 strain (evaluation of menopausal symptoms and eye fatigue) ⁇ 1.
• Compositions used> As the composition of the present invention, a commercially available tablet (product name: Protective Lactic Acid Bacteria L-137 Supplement) containing 10 mg of heat-treated killed Lactobacillus plantarum L-137 strain per tablet (300 mg) was used.
• the tablet also contains ingredients other than the L-137 strain (lactose, starch, sucrose fatty acid ester, etc.), but these ingredients do not have any particular effect on the following experiment.
• the symptoms in the Menopausal Symptoms Questionnaire were 11 items: (1) vasomotor-like symptoms, (2) sensory-like symptoms, (3) insomnia, (4) nervousness, (5) depression, (6) dizziness, (7) general malaise, (8) joint and muscle pain, (9) headache, (10) palpitations, and (11) feeling of being on the move.
• the results are shown in Table 1 below.
• composition containing the Lactobacillus casei L-137 strain of the present invention has the effect of improving menopausal symptoms and eye fatigue.
• the composition of the present invention has various useful effects. Therefore, for example, it is useful for treating, preventing, or improving (i) vasomotor disorder-like symptoms; (ii) sensory disorder-like symptoms; (iii) insomnia; (iv) nervousness; (v) depression; (vi) dizziness; (vii) general malaise; (viii) joint pain and/or muscle pain; (ix) headache; (x) palpitations; (xi) formication; and (xii) eye fatigue, and the composition is useful as a food or drink, medicine, or quasi-drug, etc.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Mycology (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Microbiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Food Science & Technology (AREA)
• Ophthalmology & Optometry (AREA)
• Polymers & Plastics (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Nutrition Science (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (4)

Applications Claiming Priority (1)

Publications (1)

Family

ID=91323345

Family Applications (1)

Country Status (4)

Citations (8)

Family Cites Families (2)

• 2022
  • 2022-11-29 JP JP2024561008A patent/JP7686892B2/ja active Active
  • 2022-11-29 WO PCT/JP2022/043911 patent/WO2024116265A1/ja not_active Ceased
  • 2022-11-29 CN CN202280100728.4A patent/CN119923266A/zh active Pending
  • 2022-11-29 EP EP22967100.3A patent/EP4628089A1/en active Pending

Patent Citations (8)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events